Jazz Pharmaceuticals plc
Symbool: JAZZ
NASDAQ
124.79
USDMarktprijs vandaag
16.5122
Koers/Winst Verhouding
0.0368
Koers/Winst Groei Verhouding
7.78B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Jazz Pharmaceuticals plc (JAZZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5742.22 | 1626.3 | 881.5 | 591.4 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 930 | 420 | 30 | 0 | |||||||||||||||||||
balance-sheet.row.net-receivables | 2567.96 | 705.8 | 651.5 | 563.4 | |||||||||||||||||||
balance-sheet.row.inventory | 2540.86 | 597 | 714.1 | 1072.7 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 754.22 | 334.8 | 267.2 | 252.4 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 12304.18 | 3263.9 | 2606.1 | 2611.3 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1123.89 | 235 | 301.4 | 343.4 | |||||||||||||||||||
balance-sheet.row.goodwill | 6924.57 | 1753.1 | 1692.7 | 1827.6 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 22305.88 | 5418 | 5794.4 | 7152.3 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29230.45 | 7171.2 | 7487.1 | 8979.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 25.24 | 4.7 | 5.5 | 12 | |||||||||||||||||||
balance-sheet.row.tax-assets | 1771.38 | 477.8 | 376.2 | 311.1 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 449.94 | 240.7 | 58.9 | 40.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 32600.91 | 8129.4 | 8229.1 | 9687.3 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 44905.09 | 11393.4 | 10835.3 | 12298.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 436.48 | 102.8 | 90.8 | 100.3 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1324.61 | 624.4 | 31 | 31 | |||||||||||||||||||
balance-sheet.row.tax-payables | 231.72 | 35.1 | 7.7 | 9.6 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 21794.59 | 5108 | 5765.2 | 6106.1 | |||||||||||||||||||
Deferred Revenue Non Current | 64.26 | 64.3 | 0 | 0.5 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 3531.91 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 3168.01 | 774.5 | 811 | 675.9 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 25853.81 | 6119.7 | 6816.3 | 7524.1 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 297.5 | 64.3 | 71.8 | 87.2 | |||||||||||||||||||
balance-sheet.row.total-liab | 30818 | 7656.4 | 7749.5 | 8333.4 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 0.24 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 3377.81 | 878.7 | 733.6 | 830.2 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3724.13 | -841.7 | -1125.5 | -400.4 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 14433.16 | 3700 | 3477.6 | 3535.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 14087.09 | 3737 | 3085.7 | 3965.2 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 44905.09 | 11393.4 | 10835.3 | 12298.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-equity | 14087.09 | 3737 | 3085.7 | 3965.2 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 44905.09 | - | - | - | |||||||||||||||||||
Total Investments | 940.2 | 424.7 | 35.5 | 12 | |||||||||||||||||||
balance-sheet.row.total-debt | 23183.46 | 5796.7 | 5796.2 | 6137.1 | |||||||||||||||||||
balance-sheet.row.net-debt | 18191.25 | 4590.3 | 4914.7 | 5545.7 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 414.83 | 414.8 | -224.1 | -329.7 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 638.7 | 638.7 | 629.5 | 552.5 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -260.22 | -260.2 | -292.3 | 69.2 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 226.84 | 226.8 | 222 | 189 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -204.44 | -204.4 | 9.9 | -48 | |||||||||||||||||||
cash-flows.row.account-receivables | -51.88 | -51.9 | -90.1 | -92.7 | |||||||||||||||||||
cash-flows.row.inventory | -13.42 | -13.4 | -49.6 | -48.9 | |||||||||||||||||||
cash-flows.row.account-payables | 9.6 | 9.6 | -11.2 | 57 | |||||||||||||||||||
cash-flows.row.other-working-capital | -148.74 | -148.7 | 160.9 | 36.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 276.29 | 276.3 | 926.9 | 345.4 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1092.01 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -24.96 | -24 | -498.2 | -45.5 | |||||||||||||||||||
cash-flows.row.acquisitions-net | -20 | 0 | 53 | -6234.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -390.1 | -390.1 | -61 | -26.8 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 270 | 270 | 60 | 1095 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 2 | -19 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -163.06 | -163.1 | -446.2 | -5212.1 | |||||||||||||||||||
cash-flows.row.debt-repayment | -31 | -31 | -582 | -1320.6 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 46.46 | 46.5 | 98 | 135.3 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | -313.03 | -269.8 | -0.1 | -35.6 | |||||||||||||||||||
cash-flows.row.dividends-paid | -112.28 | 0 | -98 | -99.7 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 104.59 | -51 | 52.6 | 5291.1 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -305.25 | -305.3 | -529.5 | 3970.5 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.14 | 1.1 | -6.2 | -3.2 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 634.83 | 354.8 | 290 | -466.3 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 4992.22 | 1206.3 | 881.5 | 591.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 4357.39 | 851.5 | 591.4 | 1057.8 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 1092.01 | 1092 | 1272 | 778.5 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -24.96 | -24 | -498.2 | -45.5 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 1067.05 | 1068 | 773.8 | 733 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3834.2 | 3834.2 | 3659.4 | 3094.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 587.13 | 1043.9 | 540.5 | 440.8 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 3247.07 | 2790.3 | 3118.9 | 2653.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 849.66 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 1286.53 | 1476.9 | 599.2 | 525.8 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 2587.77 | 2131.1 | 2606.6 | 2483.2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 3174.9 | 3174.9 | 3147.1 | 2924 | ||||||||||||||||||||
income-statement-row.row.interest-income | 65.2 | 65.1 | 11.5 | 1.8 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 308.77 | 351.1 | 288.2 | 278.8 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -215.41 | -361.4 | -885.1 | -283.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 1286.53 | 1476.9 | 599.2 | 525.8 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -215.41 | -361.4 | -885.1 | -283.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 308.77 | 351.1 | 288.2 | 278.8 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 632.12 | 638.7 | 599.2 | 525.8 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 1290.43 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 658.31 | 659.3 | 512.3 | 170.3 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 297.93 | 297.9 | -372.8 | -112.8 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | -119.91 | -119.9 | -158.6 | 216.1 | ||||||||||||||||||||
income-statement-row.row.net-income | 414.83 | 414.8 | -214.1 | -329 |
Vaak gestelde vragen
Wat is Jazz Pharmaceuticals plc (JAZZ) totale activa?
Jazz Pharmaceuticals plc (JAZZ) totale activa is 11393359000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 1984075000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.847.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.108.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.172.
Wat is Jazz Pharmaceuticals plc (JAZZ) nettowinst (netto-inkomen)?
De nettowinst is 414832000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 5796653000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 2131063000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 1206310000.000.